

Special Issue

Driving Progress in Urological Cancer Outcomes: Predictive Factors and Treatment Innovations

Message from the Guest Editor

Urological cancers remain a heterogeneous group of diseases with evolving diagnostic pathways, prognostic determinants, and therapeutic strategies. This Special Issue aims to provide an updated and comprehensive overview of current treatment outcomes and emerging prognostic factors across the spectrum of urological malignancies. By integrating clinical, molecular, and real-world evidence, the issue seeks to highlight advances that refine patient stratification, optimize therapeutic decision-making, and guide personalized care. Contributions will contextualize new findings within existing literature while identifying gaps that warrant future research. This collection intends to serve as a valuable reference for clinicians, researchers, and stakeholders dedicated to improving outcomes in urologic oncology.

Guest Editor

Dr. Juan Gómez Rivas

Department of Urology, Health Research Institute of Clínico San Carlos Hospital, Clínico San Carlos Hospital, Complutense University, 28040 Madrid, Spain

Deadline for manuscript submissions

31 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/268652

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)